Akston Launches Clinical Trial for Innovative Once-Weekly GLP-1 Weight Management Therapy for Cats

Akston's Pioneering Approach to Feline Obesity

Akston, dubbed "the Biotech Built for Pets," has recently announced the commencement of a clinical trial at Cornell University's College of Veterinary Medicine. This study focuses on evaluating an innovative once-weekly GLP-1 weight-management therapy specifically designed for overweight cats. Excess weight in felines is a pressing issue, with a staggering 61% of cats in the U.S. classified as overweight or obese in 2022, according to the Association for Pet Obesity Prevention (APOP). The need for new veterinary tools to combat this growing problem is more significant than ever.

In light of this alarming trend, Akston aims to bridge the gap in veterinary care by providing a therapy that promises to simplify the weight-management journey for cats. The trial, scheduled to span approximately three months, will treat client-owned domestic cats that are currently struggling with excess weight. So far, Akston is looking to enroll 70 cats initially, with the potential to expand to 140 participants, bringing hope to many cat owners who are eager to see their pets achieve a healthier body condition.

Todd Zion, co-founder and CEO of Akston, highlighted the significance of this initiative, stating, "Feline obesity is one of the most common yet least effectively treated health issues in veterinary medicine. By advancing a once-weekly GLP-1 therapy, we're addressing a real unmet need and aiming to give cats the chance at longer, healthier lives." This commitment to enhancing feline health could pave the way for revolutionary changes in cat care.

The GLP-1 therapy being tested is a next-generation protein designed to help cats effectively regulate their appetite. Preclinical studies carried out on laboratory cats at Cornell University revealed no adverse effects from the treatment, raising hopes for its successful application in everyday pet care. Additionally, pharmacokinetics analysis has shown that the therapy is supportive of once-weekly dosing, making it a convenient option for both veterinarians and pet owners.

"Delivering a tool for veterinarians to more effectively manage cats with excess weight would be a true breakthrough, offering a safe and effective option where one doesn't currently exist," commented Dr. Patrick Carney, Associate Professor of Clinical Sciences at Cornell University. This sentiment reflects the enthusiasm surrounding the study, as many cat owners are keen to enroll their pets and assist in the approval process for the therapy.

As Akston advances its GLP-1 program for cats, an analogous therapy for dogs is also in development, albeit approximately six months behind the feline initiative. Should the clinical trials yield successful results, the potential exists for a significant market expansion in companion-animal obesity therapies. Akston's goal is to advance treatments swiftly from discovery through to commercial manufacturing, ensuring that innovation reaches the veterinarians caring for our beloved pets more efficiently.

In conclusion, with high levels of feline obesity signaling a demand for effective weight-management solutions, Akston's pioneering approach could mark a significant step forward in veterinary medicine. By harnessing proprietary technology and focusing on the needs of pets, Akston is not just treating a symptom; they are forging a path toward healthier, happier lives for cats everywhere.

For more information about Akston and its innovative therapies, interested parties can visit www.akstonbio.com.